Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial | Zendy

Francesco Locatelli | Zendy; Nada Dimković | Zendy; Goce Spasovski | Zendy

Open Access

Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial

Author(s) -

Francesco Locatelli,

Nada Dimković,

Goce Spasovski

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft064

Subject(s) - medicine , hyperphosphatemia , kidney disease , placebo , dialysis , sevelamer , gastroenterology , phosphate binder , hemodialysis , randomized controlled trial , cholesterol , urology , endocrinology , pathology , alternative medicine

Colestilan is a non-absorbed, non-calcium-based, phosphate binder. It also binds bile acids and reduces serum levels of low-density lipoprotein cholesterol (LDL-C). This study evaluated the efficacy of a range of fixed doses of colestilan compared with placebo for the control of serum phosphorus and LDL-C levels in patients with CKD stage 5 on dialysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research